IL142490D0 - ENZYMATIC SYNTHESIS OF ssDNA - Google Patents

ENZYMATIC SYNTHESIS OF ssDNA

Info

Publication number
IL142490D0
IL142490D0 IL14249099A IL14249099A IL142490D0 IL 142490 D0 IL142490 D0 IL 142490D0 IL 14249099 A IL14249099 A IL 14249099A IL 14249099 A IL14249099 A IL 14249099A IL 142490 D0 IL142490 D0 IL 142490D0
Authority
IL
Israel
Prior art keywords
ssdna
enzymatic synthesis
enzymatic
synthesis
Prior art date
Application number
IL14249099A
Original Assignee
Ingene Inc
Cytogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16979398A priority Critical
Priority to US39778399A priority
Application filed by Ingene Inc, Cytogenix Inc filed Critical Ingene Inc
Priority to PCT/US1999/023933 priority patent/WO2000022113A1/en
Publication of IL142490D0 publication Critical patent/IL142490D0/en

Links

IL14249099A 1998-10-09 1999-10-12 ENZYMATIC SYNTHESIS OF ssDNA IL142490D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16979398A true 1998-10-09 1998-10-09
US39778399A true 1999-09-16 1999-09-16
PCT/US1999/023933 WO2000022113A1 (en) 1998-10-09 1999-10-12 ENZYMATIC SYNTHESIS OF ssDNA

Publications (1)

Publication Number Publication Date
IL142490D0 true IL142490D0 (en) 2002-03-10

Family

ID=26865381

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14249099A IL142490D0 (en) 1998-10-09 1999-10-12 ENZYMATIC SYNTHESIS OF ssDNA

Country Status (8)

Country Link
EP (1) EP1117776A1 (en)
JP (1) JP2002527061A (en)
AU (1) AU6430599A (en)
BR (1) BR9914772A (en)
CA (1) CA2346155A1 (en)
IL (1) IL142490D0 (en)
MX (1) MXPA01003642A (en)
WO (1) WO2000022113A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419964B2 (en) * 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for the inhibition of expression of a given gene
KR20020059608A (en) * 1999-10-04 2002-07-13 조나단 에프. 엘리스톤 Altering Gene Expression with ssDNA Produced in vivo
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
DE10100586C1 (en) 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
MXPA04005747A (en) * 2001-12-14 2005-07-05 Univ Yale Intracellular generation of single-stranded dna.
JP4937899B2 (en) 2004-03-12 2012-05-23 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
EP1802754A2 (en) * 2004-09-28 2007-07-04 CytoGenix, Inc. Single-stranded antimicrobial oligonucleotides and uses thereof
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
EP2527354A1 (en) 2006-03-31 2012-11-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 gene
US7691824B2 (en) 2006-04-28 2010-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the JC virus
KR101036126B1 (en) 2006-05-11 2011-05-23 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for inhibiting expression of the PCSK9 gene
AT528008T (en) 2006-05-19 2011-10-15 Alnylam Pharmaceuticals Inc Rnai-modulation of aha and their therapeutic use
AU2007253677B2 (en) 2006-05-22 2011-02-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
EP2069380B1 (en) 2006-09-18 2014-11-12 Alnylam Pharmaceuticals Inc. Rnai modulation of scap and therapeutic uses thereof
US20090209478A1 (en) 2006-09-21 2009-08-20 Tomoko Nakayama Compositions and methods for inhibiting expression of the hamp gene
PE00642009A1 (en) 2007-03-26 2009-03-02 Novartis Ag ribonucleic acid double strand to inhibit expression of the human E6AP gene and pharmaceutical composition comprising
EP2316943B1 (en) 2007-07-05 2013-06-19 Novartis AG DSRNA for treating viral infection
EP2617828B1 (en) 2007-12-10 2014-09-24 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of factor VII gene
EA019531B1 (en) 2008-03-05 2014-04-30 Элнилэм Фармасьютикалз, Инк. COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION Eg5 and VEGF
WO2010028054A1 (en) 2008-09-02 2010-03-11 Alnylam Europe Ag. Compositions and methods for inhibiting expression of mutant egfr gene
JP5529142B2 (en) 2008-09-25 2014-06-25 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Lipid formulations compositions and methods for inhibiting the expression of serum amyloid a gene
EA201792626A1 (en) 2008-10-20 2018-08-31 Элнилэм Фармасьютикалз, Инк. Compositions and methods for inhibiting transtiretin expression
CA2746514C (en) 2008-12-10 2018-11-27 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
MX2011007776A (en) 2009-02-03 2011-08-12 Hoffmann La Roche Compositions and methods for inhibiting expression of ptp1b genes.
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
CN104922699A (en) 2009-03-12 2015-09-23 阿尔尼拉姆医药品有限公司 LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
KR20120050429A (en) 2009-06-15 2012-05-18 알닐람 파마슈티칼스 인코포레이티드 Lipid formulated dsrna targeting the pcsk9 gene
US20110112176A1 (en) 2009-11-09 2011-05-12 John Frederick Boylan Compositions and methods for inhibiting expression of kif10 genes
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
US20110196016A1 (en) 2010-02-05 2011-08-11 Anke Geick Compositions and Methods for Inhibiting Expression of IKK2 Genes
CA2792291A1 (en) 2010-03-29 2011-10-06 Kumamoto University Sirna therapy for transthyretin (ttr) related ocular amyloidosis
CA2801066A1 (en) 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
EP2630240A1 (en) 2010-10-18 2013-08-28 Arrowhead Research Corporation Compositions and methods for inhibiting expression of rrm2 genes
EP2648763A4 (en) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
MX344807B (en) 2011-06-21 2017-01-09 Alnylam Pharmaceuticals Inc Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes.
WO2012177921A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
WO2012177784A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
WO2012178033A2 (en) 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
NZ617756A (en) 2011-06-30 2015-04-24 Arrowhead Res Corp Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2013019857A2 (en) 2011-08-01 2013-02-07 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
JP2016506240A (en) 2012-12-05 2016-03-03 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. PCSK9iRNA compositions and methods of use thereof
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
SG11201507400SA (en) 2013-03-14 2015-10-29 Alnylam Pharmaceuticals Inc Complement component c5 irna compositions and methods of use thereof
DK2999785T3 (en) 2013-05-22 2018-07-23 Alnylam Pharmaceuticals Inc Serpina1-iRNA compositions and methods of use thereof
RU2015154738A (en) 2013-05-22 2017-06-27 Элнилэм Фармасьютикалз, Инк. COMPOSITION FOR iRNA TMPRSS6 BASIS AND METHODS OF THEIR USE
WO2015050990A1 (en) 2013-10-02 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
CA2925129A1 (en) 2013-10-04 2015-04-09 Novartis Ag 3'end caps for rnai agents for use in rna interference
US9988627B2 (en) 2013-10-04 2018-06-05 Novartis Ag Formats for organic compounds for use in RNA interference
CA2938857A1 (en) 2014-02-11 2015-08-20 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
BR112016026950A2 (en) 2014-05-22 2017-10-31 Alnylam Pharmaceuticals Inc RNAi compositions angiotensinogen (AGT), and methods of use thereof
BR112017008868A2 (en) 2014-11-10 2018-01-16 Alnylam Pharmaceuticals Inc IRNA compositions of the hepatitis B virus (HBV) and methods for their use
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016130806A2 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3283631A1 (en) 2015-04-13 2018-02-21 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP3292201A2 (en) 2015-05-06 2018-03-14 Alnylam Pharmaceuticals, Inc. Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
US20180201929A1 (en) 2015-07-10 2018-07-19 Alnylam Pharmaceuticals, Inc. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2018523668A (en) 2015-08-07 2018-08-23 アローヘッド ファーマシューティカルズ インコーポレイテッド RNAi therapy for hepatitis B virus infection
CN108368507A (en) 2015-09-02 2018-08-03 阿尔尼拉姆医药品有限公司 PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2017048843A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
CN108601795A (en) 2015-12-07 2018-09-28 建新公司 Methods and compositions for treating a serpinc1-associated disorder
WO2017100542A1 (en) 2015-12-10 2017-06-15 Alnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
WO2017184689A1 (en) 2016-04-19 2017-10-26 Alnylam Pharmaceuticals, Inc. High density lipoprotein binding protein (hdlbp/vigilin) irna compositions and methods of use thereof
WO2017214518A1 (en) 2016-06-10 2017-12-14 Alnylam Pharmaceuticals, Inc. COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
TW201829443A (en) 2016-11-23 2018-08-16 美商阿尼拉製藥公司 Serine proteinase inhibitor factor A1 iRNA composition and method of use
WO2019089922A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2019099610A1 (en) 2017-11-16 2019-05-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019126097A1 (en) 2017-12-18 2019-06-27 Alnylam Pharmaceuticals, Inc. High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
US20190185948A1 (en) 2017-12-20 2019-06-20 Roche Molecular Systems, Inc. Non-replicative transduction particles and transduction particle-based reporter systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436141A (en) * 1989-02-24 1995-07-25 University Of Medicine And Dentistry Of New Jersey Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products
US5434070A (en) * 1989-02-24 1995-07-18 The University Of Medicine And Dentistry Of New Jersey Reverse transcriptases from Escherichia coli and Myxococcus xanthus
CA2073630C (en) * 1991-08-30 2007-12-11 Atsushi Ohshima Method for synthesizing single-stranded stem-loop dnas, the products and uses therefor
WO1994020639A1 (en) * 1991-08-30 1994-09-15 The University Of Medicine And Dentistry Of New Jersey Over expession of single-stranded molecules
CZ333294A3 (en) * 1992-07-02 1995-07-12 Hybridon Self-stabilized oligonucleotide and inhibition method of virus gene or pathogenic organism or cellular gene expression
AU5871094A (en) * 1992-12-09 1994-07-04 Jeffrey E. Miller Methods and compositions for cdna synthesis
FR2703053B1 (en) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides staples and semi-staples, process for the preparation and applications.
JPH10501974A (en) * 1994-06-22 1998-02-24 イー. ミラー,ジェフリー Methods and compositions for the cDNA synthesis

Also Published As

Publication number Publication date
AU6430599A (en) 2000-05-01
CA2346155A1 (en) 2000-04-20
EP1117776A1 (en) 2001-07-25
WO2000022113A1 (en) 2000-04-20
WO2000022113A9 (en) 2000-08-24
BR9914772A (en) 2001-12-11
JP2002527061A (en) 2002-08-27
MXPA01003642A (en) 2003-07-21

Similar Documents

Publication Publication Date Title
GB2336065B (en) Miniature transducer
DE69926903D1 (en) Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
AU3052899A (en) Determination of apnea type
IL138113D0 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
PL218882B1 (en) New derivatives of 3,3-diphenylpropylamines
PL342759A1 (en) Novel medium
HRP20000551A2 (en) Inhibitors of phospholipase enzymes
AU5492499A (en) Signal generating oligonucleotide-based biosensor
PL342995A1 (en) Inhibitors of phospholipase enzymes
AU7902500A (en) Improved synthesis of racemic sertraline
PL193283B1 (en) Derivatives of n-arylphenylalanine
PL199355B1 (en) Method of obtaining axazolydinones
PL195192B1 (en) Derivatives of rezorcin
EP1127054A4 (en) Novel inhibitors of impdh enzyme
AU8589698A (en) Selective synthesis of organodiphosphite compounds
ZA200104004B (en) Process for the synthesis of azetidinones.
PL341294A1 (en) Method of synthesising 1,3-dioles
IL124903D0 (en) An enzyme biosensor
AU1430699A (en) Production of propylene
IL137361D0 (en) Inhibitors of the cd40 ligand-cd40 interaction
GB9606187D0 (en) Production of vanillin
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
SI1075477T1 (en) Novel Benzonaphthyridine-N-oxides
TW399786U (en) Improvememt of receptacle structure
AU2792499A (en) Improved methods for synthesis of oligonucleotides